EA200500084A1 - Фармацевтическая композиция для чрескожной доставки активного агента - Google Patents

Фармацевтическая композиция для чрескожной доставки активного агента

Info

Publication number
EA200500084A1
EA200500084A1 EA200500084A EA200500084A EA200500084A1 EA 200500084 A1 EA200500084 A1 EA 200500084A1 EA 200500084 A EA200500084 A EA 200500084A EA 200500084 A EA200500084 A EA 200500084A EA 200500084 A1 EA200500084 A1 EA 200500084A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active agent
physiologically active
pharmaceutical composition
volatile solvent
skin
Prior art date
Application number
EA200500084A
Other languages
English (en)
Other versions
EA009024B1 (ru
Inventor
Кэтрин Трейси-Джейн Клоус
Тимоти Матиас Морган
Барри Леонард Рид
Нина Франсис Уилкинс
Барри Чарльз Финнин
Original Assignee
АКРУКС ДиДиЭс ПиТиУай ЭлТиДи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200500084(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by АКРУКС ДиДиЭс ПиТиУай ЭлТиДи filed Critical АКРУКС ДиДиЭс ПиТиУай ЭлТиДи
Publication of EA200500084A1 publication Critical patent/EA200500084A1/ru
Publication of EA009024B1 publication Critical patent/EA009024B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Представлена фармацевтическая композиция для чрескожной доставки, содержащая один или более физиологически активных агентов, один или более агентов, способствующих проникновению через кожу, и летучий фармацевтически приемлемый носитель, содержащий летучий растворитель, причем физиологически активный агент и агент, способствующий проникновению через кожу, образуют аморфное отложение при испарении летучего растворителя, данное аморфное отложение образует резервуар в ороговевающем слое кожи, и при этом композиция имеет такой профиль скорости высвобождения физиологически активного агента, который обеспечивает соотношение максимальной концентрации (C) и средней концентрации (C) физиологически активного агента в интервале между введениями препарата в пределах от 1 до 10.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200500084A 2002-06-25 2003-06-24 Фармацевтическая композиция для чрескожной доставки активного агента (варианты) EA009024B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39108102P 2002-06-25 2002-06-25
PCT/AU2003/000787 WO2004000263A1 (en) 2002-06-25 2003-06-24 Transdermal delivery rate control using amorphous pharmaceutical compositions

Publications (2)

Publication Number Publication Date
EA200500084A1 true EA200500084A1 (ru) 2005-06-30
EA009024B1 EA009024B1 (ru) 2007-10-26

Family

ID=30000668

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200500084A EA009024B1 (ru) 2002-06-25 2003-06-24 Фармацевтическая композиция для чрескожной доставки активного агента (варианты)

Country Status (12)

Country Link
US (4) US8357393B2 (ru)
EP (2) EP1534235B1 (ru)
JP (2) JP5160018B2 (ru)
KR (2) KR20050045946A (ru)
AU (1) AU2003240301B2 (ru)
BR (1) BRPI0312007B1 (ru)
CA (1) CA2489865C (ru)
EA (1) EA009024B1 (ru)
ES (1) ES2589077T3 (ru)
HK (1) HK1077192A1 (ru)
NZ (1) NZ537360A (ru)
WO (1) WO2004000263A1 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
KR20050045946A (ko) 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
ATE295726T1 (de) * 2002-12-02 2005-06-15 Sanol Arznei Schwarz Gmbh Verabreichung von rotigotine zur behandlung der parkinson'schen krankheit durch iontophorese
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
GB0306859D0 (en) * 2003-03-25 2003-04-30 Arachnova Therapeutics Ltd Topical formulation and use of buspirone
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
US20060263421A1 (en) 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
ES2607454T3 (es) * 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona
MX2007015255A (es) * 2005-06-03 2008-02-22 Acrux Dds Pty Ltd Metodo y composicion para administracion transdermica de un farmaco.
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
ES2533463T3 (es) 2006-10-12 2015-04-10 Bhi Limited Partnership Métodos, compuestos, composiciones y vehículos para suministrar ácido 3-amino-1-propanosulfónico
AU2007343579B2 (en) 2007-01-11 2011-11-17 Acrux Dds Pty Ltd Spreading implement
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
PL2219603T3 (pl) * 2007-11-02 2014-10-31 Acrux Dds Pty Ltd Układ transdermalnego dostarczania
KR100929560B1 (ko) * 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
UA103851C2 (en) 2010-04-30 2013-11-25 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Propylaminoindan transdermal composition
CN103930105B (zh) * 2010-12-02 2019-11-01 尼克美控股公司 2-(n,n-二甲基氨基)-丙酸十二烷基酯的活性对映体
KR101526781B1 (ko) 2011-02-15 2015-06-05 일라이 릴리 앤드 캄파니 펜타닐의 경피 용액을 사용하여 개에서 통증을 제어하는 방법
ES2784627T3 (es) * 2011-02-15 2020-09-29 Audevard Métodos para controlar el dolor en equinos utilizando una disolución transdérmica de fentanilo
EP2688561B1 (en) 2011-03-24 2018-08-22 Teikoku Pharma USA, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2776020B1 (en) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Methods for the treatment of skin neoplasms
EA031621B1 (ru) 2012-11-02 2019-01-31 ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. Трансдермальная композиция на основе пропиниламиноиндана, содержащий такие композиции набор и способ доставки пропиниламиноиндана
CA2906796A1 (en) * 2013-03-15 2014-09-25 Nal Pharmaceuticals Ltd. Transdermal drug delivery system containing rivastigmine
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
WO2016154232A2 (en) 2015-03-23 2016-09-29 BioPharmX, Inc. Pharmaceutical tetracycline composition for dermatological use
JP2018177724A (ja) * 2017-04-18 2018-11-15 花王株式会社 外用薬
US11523994B2 (en) 2018-01-10 2022-12-13 Celista Pharmaceuticals Llc Testosterone transdermal spray with film
AU2019299538A1 (en) * 2018-07-05 2021-01-28 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (ru) * 1956-03-21 1900-01-01
GB1192003A (en) 1966-05-25 1970-05-13 Struthers Scientific Int Corp Improvements in or relating to Hair Dressing Preparation
GB1258394A (ru) 1968-01-17 1971-12-30
GB1560401A (en) 1976-01-28 1980-02-06 Unilever Ltd Skin treatment composition
DE2920500A1 (de) 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
US4506803A (en) * 1982-08-09 1985-03-26 Hoffmann-La Roche Inc. Metered aerosol dispenser and method of using the dispenser
DE3311700A1 (de) * 1983-03-30 1984-10-04 Bayer Ag Antimykotische mittel mit hoher wirkstoff-freisetzung in form von loesung und spray
US4912124A (en) * 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
US5008111A (en) 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4824676A (en) 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4820724A (en) 1986-03-31 1989-04-11 University Of Southern California Dual phase solvent carrier system
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5082866A (en) * 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US5164406A (en) 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
US5788983A (en) 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
EP0408019A3 (en) 1989-07-12 1992-10-14 Union Carbide Chemicals And Plastics Company, Inc. Pharmaceutical active derivative delivery systems
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
JPH0794378B2 (ja) 1989-08-18 1995-10-11 久光製薬株式会社 エアゾール剤
JPH0383924A (ja) 1989-08-28 1991-04-09 Kanebo Ltd 経皮投与用組成物
IL95952A0 (en) * 1989-10-19 1991-07-18 Sterling Drug Inc Aerosol composition for topical medicament
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JP2974081B2 (ja) 1990-07-26 1999-11-08 小池化学株式会社 人体用エアゾール組成物
DE69105212T2 (de) 1990-10-18 1995-03-23 Minnesota Mining & Mfg Aerosolzubereitung, die beclometason 17,21-dipropionat enthält.
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
DE69222182T2 (de) * 1991-12-18 1998-02-26 Warner Lambert Co Verfahren für die herstellung einer festen dispersion
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
DK0644746T3 (da) 1992-06-11 1999-12-20 Theratech Inc Anvendelse af glycerin til moderering af transdermal lægemiddelafgivelse
CA2101496A1 (en) 1992-07-31 1994-02-01 Masao Kobayashi Base for transdermal administration
DE4230588C1 (de) 1992-09-12 1993-10-07 Lohmann Therapie Syst Lts Dexpanthenol-haltiges Pflaster zur transdermalen Applikation von Steroidhormonen und Verfahren zu seiner Herstellung
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4334553C2 (de) * 1993-10-11 1998-05-20 Synopharm Gmbh Pharmazeutische Flüssiges pharmazeutisches System zur perkutanen Applikation
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
US6998138B2 (en) * 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
DE19616539A1 (de) * 1996-04-25 1997-11-06 Luitpold Pharma Gmbh Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
AUPO379596A0 (en) * 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US5968919A (en) 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
KR100648536B1 (ko) 1997-11-10 2006-11-24 셀러지 파마세우티칼스, 인크 침투 보강 및 자극 감소를 위한 계
EP0919550A1 (en) * 1997-11-26 1999-06-02 Ucb, S.A. Pseudopolymorphic forms of 2-2-4-bis(4-fluorophenyl)methyl-1-piperazinyl-ethoxy acetic acid dihydrochloride
NZ509489A (en) * 1998-08-04 2002-10-25 Jago Res A Medicinal aerosol formulations comprising cromoglycic acid and/or nedocromil
US5962505A (en) * 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19843027A1 (de) * 1998-09-19 2000-03-23 Labtec Gmbh Neohesperidin DC als Kristallisationsinhibitor
US6663874B2 (en) * 1998-11-02 2003-12-16 Victor Stevens Composition to alleviate pain and topical method of applying same
DK1150661T3 (da) * 1999-02-05 2004-03-01 Cipla Ltd Topiske sprays der omfatter et filmdannende præparat
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
JP2001270826A (ja) 1999-09-28 2001-10-02 Shoei:Kk 皮膚疾患治療・予防用外用剤
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
WO2001041755A2 (en) * 1999-12-02 2001-06-14 The Regents Of The University Of Michigan Topical compositions comprising thalidomide for the treatment of inflammatory diseases
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
JP2004159666A (ja) * 1999-12-21 2004-06-10 Ya Man Ltd レーザ脱毛器
IN191512B (ru) * 2000-01-21 2003-12-06 Panacea Biotech
US6562790B2 (en) 2000-02-05 2003-05-13 Chein Edmund Y M Hormone therapy methods and hormone products for abating coronary artery blockage
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
IN191090B (ru) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DK1315502T3 (da) 2000-08-30 2010-07-19 Unimed Pharmaceuticals Llc Fremgangsmåde til behandling af erektil dysfunktion og til forøgelse af mænds libido
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
BR0113649A (pt) 2000-08-30 2004-07-20 Unimed Pharmaceuticals Inc Processo para aumentar a testosterona e as relacionadas concentrações de esteróide em mulheres
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
GB0029634D0 (en) * 2000-12-05 2001-01-17 Norway Medical Group Int As Use
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
US20050084553A1 (en) 2002-01-26 2005-04-21 Woong-Sig Moon Composition containing moutan root bark extract as active ingredient
US20030199584A1 (en) 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
KR20050045946A (ko) * 2002-06-25 2005-05-17 애크럭스 디디에스 피티와이 리미티드 비정질 약학적 조성물을 이용한 경피전달속도의 제어
AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
US8206696B2 (en) 2002-12-30 2012-06-26 Aplicare, Inc. Antimicrobial skin preparation
GB0302662D0 (en) 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
PL1670433T3 (pl) 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
CN1882340A (zh) * 2003-11-19 2006-12-20 艾克若克斯Dds有限公司 用于治疗或预防淀粉样变性病的方法和组合物
US20050123576A1 (en) 2003-12-03 2005-06-09 Ilana Lavon Mupirocin compositions for topical use, an improved process of making same and methods of using same
NZ592041A (en) 2004-03-03 2012-12-21 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1634583A1 (en) 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
ES2607454T3 (es) * 2005-06-03 2017-03-31 Acrux Dds Pty Ltd Método y composición para el suministro transdérmico de testosterona

Also Published As

Publication number Publication date
EP2266533A3 (en) 2011-12-14
JP5160018B2 (ja) 2013-03-13
JP2006501172A (ja) 2006-01-12
EP2266533A2 (en) 2010-12-29
EP1534235A4 (en) 2008-06-18
KR20050045946A (ko) 2005-05-17
JP2012162557A (ja) 2012-08-30
US8784878B2 (en) 2014-07-22
EA009024B1 (ru) 2007-10-26
JP5568108B2 (ja) 2014-08-06
HK1077192A1 (zh) 2006-02-10
EP1534235A1 (en) 2005-06-01
US8357393B2 (en) 2013-01-22
US20130316996A1 (en) 2013-11-28
NZ537360A (en) 2006-09-29
CA2489865A1 (en) 2003-12-31
WO2004000263A1 (en) 2003-12-31
KR20100055542A (ko) 2010-05-26
AU2003240301A1 (en) 2004-01-06
CA2489865C (en) 2012-05-08
US20050175680A1 (en) 2005-08-11
AU2003240301B2 (en) 2008-02-14
US20100166674A1 (en) 2010-07-01
ES2589077T3 (es) 2016-11-10
BRPI0312007B1 (pt) 2015-04-14
EP1534235B1 (en) 2016-07-27
BR0312007A (pt) 2005-04-12
US20150094290A1 (en) 2015-04-02

Similar Documents

Publication Publication Date Title
EA200500084A1 (ru) Фармацевтическая композиция для чрескожной доставки активного агента
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
CA3073442C (en) Method of rapidly achieving therapeutic concentrations of zolmitriptan for treatment of migraines and cluster headaches
IN2015DN01132A (ru)
RU99117926A (ru) Лекарственные формы и способ лечения расстройства мужской эректильной функции
EP0857488A3 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
EP0857488A1 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
JPH0784380B2 (ja) 活性成分としてフィゾステイグミンを有する皮膚経由医薬及びその製造方法
CO5261593A1 (es) Formulaciones de entecavir de dosis bajas y uso
US11660264B2 (en) Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
US9918932B2 (en) Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines
DK1311248T3 (da) Transdermalt terapeutisk system til behandling af Restless Legs syndromet
WO2000013662A8 (en) Medicated chewing gum delivery system for nicotine
US11660265B2 (en) Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
WO2006091719A3 (en) Compositions and methods enhancing transdermal delivery of drugs and biologics
JP2013537906A (ja) 増強型経頬薬剤送達系および組成物
US20050181032A1 (en) Metastable pharmaceutical compositions
EA200500082A1 (ru) Фармацевтическая композиция для чрескожной доставки физиологически активных агентов
KR20120056322A (ko) 자나미비르를 유효성분으로 하는 경피제
CN1146721A (zh) 通过指甲给药的全身药物输送系统
US20230255881A1 (en) Method of rapidly achieving therapeutic concentrations of triptans for treatment of migraines and cluster headaches
CN1226163A (zh) 治疗和/或预防痴呆的制剂
EA200500083A1 (ru) Фармацевтическая композиция для чрескожной доставки активного агента (варианты)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU